Clinical Trial Update: Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating topical Hedgehog pathway inhibitor LDE225 cream for adults with nevoid basal cell carcinoma syndrome (NBCCS) and basal cell carcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Nevoid Basal Cell Carcinoma Syndrome

Drugs mentioned

• LDE225 Cream (sonidegib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Basal Cell Carcinoma | Phase 2, Phase 3 | Status: WITHDRAWN